Trader consensus heavily favors no hantavirus vaccine reaching approval or widespread availability by the end of 2026, reflecting the current preclinical or early Phase 1 status of all candidates. Recent mRNA work, including single-dose formulations tested in hamster models against Andes virus, and a UK Phase 1 MVA-based trial that completed enrollment in mid-2026, remain far from licensure timelines typical for novel vaccines. The lack of approved therapeutics or vaccines was underscored by the 2026 cruise ship outbreak, with no major funding surges or regulatory accelerations reported. While an unforeseen large-scale outbreak could prompt emergency-use pathways, standard development hurdles—manufacturing scale-up, multi-strain coverage, and human efficacy data—make near-term resolution improbable.